linjc16/ctgov huggingface dataset:
Metabolic and Nutritional Characteristics of Long-stayer ICU Patients

Study Overview
=================
Brief Summary
-----------------
The intensive care (ICU) patient population has increasing number of very long ICU stays. Long-stayers are usually defined as requiring more than 1 week of mechanical ventilation and of ICU therapy: little is know about their metabolic characteristics and their relation to outcome. The study aims at describing the demographic, nutritional and metabolic aspects of their stay. Analysis of 200-250 consecutive patients admitted to the ICU long-stayer program.

Detailed Description
-----------------
Data extracted from the computerized ICU system (PDMS): age, Simplified acute physiology score (SAPSII), weight, BMI, Nutrition Risk Score (NRS-2002), daily energy, protein, and glucose intakes, Energy balance, blood glucose (dysglycemia and Glu variability) and lactate, 24hr-insulin (Goal Glu 6-8 mmol/l). Outcome variables: length of stay (LICU), muscle strength (MRC), vital status at 90 days. Patients will be followed in detail until ICU discharge and for vital status until day 90 after admission Data will be presented as mean or median, univariate and multivariate analysis will be performed.

Official Title
-----------------
Long-stayer Critically Ill Patients: is the Metabolic and Nutritional Therapy in the ICU Creating the Problem?

Conditions
-----------------
Critically Ill

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ICU length of stay > 7 days and enrollment to the long-stayer ICU program Exclusion Criteria: Major burns Brain injury Severe neurological condition as primary disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Vital Status | Alive or dead at 90 days after ICU admission | up to 90 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Force | Muscle strength measured by Medical research Council (MRC) score | up to 90 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Metabolism, Energy,Glucose, Protein, Energy deficit
Taste and Smell Impairment in Critically Ill COVID-19 Patients

Study Overview
=================
Brief Summary
-----------------
Evaluating the smell and taste perceptions of patients hospitalized in the intensive care unit with suspicion of Coronavirus disease-19 diagnosis with a survey study

Detailed Description
-----------------
Patients who were treated in the intensive care unit of Şişli Hamidiye Etfal Training and Research Hospital with the diagnosis of Coronavirus disease-19 will be determined by scanning the hospital registry system. It was planned that patients discharged from the intensive care unit would be called by phone and their complaints about smell and taste disorders were evaluated with a questionnaire.

Official Title
-----------------
Taste and Smell Impairment in Critically Ill COVID-19 Patients

Conditions
-----------------
Smell Disorder, Taste Disorders, Coronavirus Infection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults between the ages of 18-80 Agree to participate in the study Patients treated in the intensive care unit with the diagnosis of Coronavirus disease-19 Exclusion Criteria: Pre-existing smell and taste impairment The patients have no enough cooperation to answer the questionnaire Having additional diseases such as dementia and Alzheimer

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| taste and smell impairment | incidence of taste and smell impairment in critically ill subjects | up to 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Coronavirus disease-19, anosmia, hyposmia, dysgeusia
Biometric Factors Changes Caused by Myopia Orthokeratology (OK) Lens

Study Overview
=================
Brief Summary
-----------------
Subjects fit with VST or CRT type lens are reviewed 1 day to 2 year after first wearing the lens. Ocular examinations were performed, including slit-lamp biomicroscope, uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), corneal topography (Medmont E300W, Medmont Pty Ltd, Melbourne, Australia), corneal refractive power (autorefractometer, KR880, Topcon, JAPAN), corneal epithelial thickness (Optical Coherence Tomography, RTVue-XR), axial length using IOL-Master 700 (Carl Zeiss Meditec AG). To investigate corneal and retina changes caused by overnight OK lens.

Official Title
-----------------
The Influence on Biometric Factors Changes by Different OK Lens

Conditions
-----------------
Contact Lenses

Intervention / Treatment
-----------------
* Device: Overnight orthokeratology


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Normal subjects without any history of ocular surgeries or diseases (except for refractive errors) or systemic diseases that might affect contact lens wearing. The spherical error between -1.0 and -5.0 D, cylindrical error of at most 2.0 D, and a corrected distance visual acuity of 20/20 or better. Exclusion Criteria: Subjects who had previously worn contact lens, were also excluded

Ages Eligible for Study
-----------------
Minimum Age: 8 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: CRT type lens<br>Subjects fitted with CRT type lenses | Device: Overnight orthokeratology<br>* Subjects require to wear the lenses every night, with a recommended time of 6-8 hours.<br>|
| Experimental: VST type lens<br>Subjects fitted with VST type lenses | Device: Overnight orthokeratology<br>* Subjects require to wear the lenses every night, with a recommended time of 6-8 hours.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change of Corneal Epithelium | All epithelial thickness and treatment zone area record by baseline and follow up examination. | up to 1 day, 1 week,1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Axial length | Axial length growth after lens wear | up to 2 years |
Pseudophakic Astigmatic Reduction With Verion-LenSx Arcuate Incisions

Study Overview
=================
Brief Summary
-----------------
To assess the effectiveness of the Verion-LenSx guided arcuate incision technique to reduce astigmatism in a pseudophakic population.

Detailed Description
-----------------
The purpose of this study is to evaluate the effectiveness of corneal arcuate incisions when they are performed with a femtosecond laser system on subjects who have had previous cataract surgery. The procedure to be used would not be different from that employed during cataract surgery, except that the only corneal incisions made would be the partial-depth arcuate incisions at the laser.

Official Title
-----------------
Pseudophakic Astigmatic Reduction With Verion-LenSx Arcuate Incisions

Conditions
-----------------
Astigmatism

Intervention / Treatment
-----------------
* Procedure: Verion-LenSx


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 40 or older Willing and able to provide informed consent for participation in the study. Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Verion-LenSx<br>The Verion-LenSx femtosecond laser system will be used to perform one or two corneal arcuate incisions. | Procedure: Verion-LenSx<br>* The Verion-LenSx femtosecond laser system will be used to create one or two partial-depth corneal arcuate incisions<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Uncorrected Monocular Distance Visual Acuity | Uncorrected monocular distance visual acuity, measured on a logMAR scale, (logarithm of the Minimum Angle of Resolution) which is a measure of visual acuity in which the smaller values indicate better visual acuity. | 60 days (+/- 10 days) after laser treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Corneal Astigmatism | Vector change in the astigmatism measured on the cornea, in diopters | 60 days (+/- 10 days) after laser treatment | 
| Change in Refractive Cylinder | The vector change in refractive cylinder in diopters | 60 days (+/- 10 days) after laser treatment | 
| Spectacle Independence at Distance | Percentage of subjects that do not rely on spectacles for distance vision | 60 days (+/- 10 days) after laser treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pseudophakic
The Effect of an Electronic Medical Record (EMR) Alert on Hepatitis B Screening

Study Overview
=================
Brief Summary
-----------------
Asian and Pacific Islander Americans at risk, but never tested for chronic hepatitis B have been randomized to receive an electronic alert in their electronic medical chart to remind primary care physicians to screen them for chronic hepatitis B.

Official Title
-----------------
The Effect of an Electronic Medical Record (EMR) Alert on Hepatitis B Screening: A Randomized Controlled Trial

Conditions
-----------------
Hepatitis B

Intervention / Treatment
-----------------
* Other: Electronic HBV Alert


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Asian and Pacific Islanders (API) who have not yet received HBsAg testing. API will be identified using a novel algorithm which identifies them using their surname, language preference, country of origin. - Exclusion Criteria: Previous HBsAg completion. -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: HBV Alert Group<br> | Other: Electronic HBV Alert<br>* Electronic HBV Alert deployed in electronic medical charts of at risk patients<br>|
| No Intervention: Control Group<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serum Hepatitis B Surface Antigen Completion | Number of patients who have completed the HBsAg test | up to 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serum Hepatitis B Surface Antigen Positivity | Number of patients with testing positive for HBsAg | up to 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Mass Screening
Comparing Cardiovascular Effects of 1:100,000 and 1:200,000 Epinephrine Solutions

Study Overview
=================
Brief Summary
-----------------
The study aim to evaluate systemic response of patients when 2 different concentrations of Epinephrine are injected during inferior alveolar nerve block for wisdom teeth extraction.

Official Title
-----------------
Randomized Double-blind Clinical Trial Comparing the Cardiovascular Effects of Local Anesthesia Solutions Containing 1:100,000 and 1:200,000 of Epinephrine Concentrations

Conditions
-----------------
Cardiovascular Response to Epinephrine

Intervention / Treatment
-----------------
* Drug: Epinephrine 1:100,000
* Drug: Epinephrine 1:200,000


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Class I patients according to the American Society of Anesthesiology (ASA), Indication for third molars extraction, Similar degree of complexity, according to the classification of Pell and Gregory. Exclusion Criteria: Patients with systemic conditions, Patients with known allergy to any component of the anesthetic solution.

Ages Eligible for Study
-----------------
Minimum Age: 13 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Epinephrine 1:100,000<br>Inferior alveolar nerve block with Epinephrine 1:100.000 | Drug: Epinephrine 1:100,000<br>* Inferior alveolar nerve block with Epinephrine 1:100.000<br>|
| Experimental: Epinephrine 1:200,000<br>Inferior alveolar nerve block with Epinephrine 1:200.000 | Drug: Epinephrine 1:200,000<br>* Inferior alveolar nerve block with Epinephrine 1:200.000<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Heart rate |  | 20 minutes | 
| Blood pressure |  | 20 minutes | 
| Arterial oxygen saturation, measured with a pulse oximeter device |  | 20 minutes | 
| Bleeding, evaluated by the surgeon as either: 1) normal or 2) excessive |  | 20 minutes | 
| Pain, evaluated using a visual analogue scale |  | After procedure, about 1 hour |
National Registry for Egyptian Pediatric Neuromuscular Diseases

Study Overview
=================
Brief Summary
-----------------
Our aim is to establish multi-center national Egyptian database of information for inherited and acquired neuromuscular diseases in infants and children from 0 to 18 years of age.

Detailed Description
-----------------
Aims: An open-ended multi-center, national Egyptian study to collect and analyze data for children with Neuromuscular Diseases (NMD) inherited NMD (spinal muscular atrophy (SMA), Duchenne/Becker and congenital muscular dystrophies (DMD/BMD, CMD), congenital myopathies, and congenital myasthenic syndromes) and acquired NMD (neuropathies, myasthenia gravis and myositis). Participants: Eligible infants and children with inherited and acquired neuromuscular diseases. DESIGN: This study is a prospective cohort study. Outcome measures: Motor development assessment, respiratory and cardiac examination.

Official Title
-----------------
National Registry for Egyptian Pediatric Neuromuscular Diseases

Conditions
-----------------
Spinal Muscular Atrophy, Muscular Dystrophy, Muscle Diseases, Myasthenic Syndromes, Polyneuropathies

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Weakness, hypotonia. Nerve conduction study and electromyographic confirmation of lower motor neuron affection. Exclusion Criteria: Chromosomal diseases. Malformations and deformations.

Ages Eligible for Study
-----------------
Minimum Age: 1 Month
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Neuromuscular diseases<br>Prospective cohort of children with inherited or acquired neuromuscular diseases. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Functional motor ability | Motor power in acquired acute neuromuscular diseases will be assessed at admission and morbidity and mortality at discharge from hospital. Functional motor ability will be performed every 3 months for children with inherited neuromuscular diseases. | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cardio-pulmonary function | Pulmonary and cardiac function impairment. | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
spinal muscular atrophy, Muscular dystrophy, Muscle diseases, myasthenic syndromes, Polyneuropathies, Myopathies
Vitamin D in Diabetic Children

Study Overview
=================
Brief Summary
-----------------
Vitamin D is so-called sunshine vitamin,it is synthesized in the skin during exposure to the ultraviolet rays in sunlight so it has been suggested that ∼ 5-30 minutes of sun exposure between 10:00 a.m. and 3:00 p.m. at least twice per week on the skin of the face, arms, back, or legs (without sunscreen) is usually adequate for vitamin D synthesis. Vitamin D is also found in plants (mainly mushrooms and yeast) and in a few foods such as fatty fish. Vitamin D supplement is recommended in all infants until enough formula, milk, or other food sources are ingested to sufficiently provide 400 IU/day to prevent vitamin D deficiency. Type 1 diabetes is an autoimmune disease, and the self immune system plays a central role in the destruction of the beta cell of pancrease.

Official Title
-----------------
Assessment of Vitamin D in Children With Type 1 Diabetes

Conditions
-----------------
Vitamin D Deficiency

Intervention / Treatment
-----------------
* Diagnostic Test: blood sample test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age (5 years - 15 years ). Type 1 diabetes patients. Exclusion Criteria: Patients aged more than 15 years, less than 2 years. Type 2 diabetes. Neonatal diabetes. Patients with any complications from diabetes.

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Blood sample<br>2ml blood sample of of blood will be taken for assessment of vitamin D | Diagnostic Test: blood sample test<br>* blood sample will be taken from all diabetic children for assessment of vitamin D level<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of vitamin D level (ng/ml) |  | 24 hours |
Pilot Study: Mobile Phone Based Physical Activity in Sedentary Men and Women

Study Overview
=================
Brief Summary
-----------------
The purpose of this pilot study is to estimate the efficacy of a mobile phone based physical activity intervention in sedentary men and women.

Official Title
-----------------
Innovations in Mobile Phone Based Physical Activity- A Pilot of Clinical Trial in Sedentary Men and Women

Conditions
-----------------
Sedentary Lifestyle, Physical Activity

Intervention / Treatment
-----------------
* Behavioral: Mobile phone
* Behavioral: pedometer only


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Sedentary lifestyle at work and/or during leisure time Male or female, age between 21-69 Access to a telephone at home or a mobile phone Speak and read English BMI between 20-43 kg/m2 Exclusion Criteria: Known medical condition or other physical problems that need special attention in an exercise program Planning a trip out of the United States during the study Pregnant/Delivered a baby during the last 6 months HIV positive Known severe hearing or speech problems Currently participating in lifestyle modification programs or research studies (such as physical activity, diet, and/or weight loss programs)

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 69 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: pedometer<br> | Behavioral: pedometer only<br>* Participants in this group will receive only a pedometer.<br>|
| Experimental: Mobile phone physical activity intervention<br> | Behavioral: Mobile phone<br>* Participants in this group will receive both the pedometer and the mobile-phone based physical activity intervention fot three months.<br>* Other names: Mobile phone based physical activity intervention;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pedometer measured steps |  | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 7-Day Physical Activity Recall |  | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Mobile phone, Sedentary lifestyle, Physical activity, Prevention, Health Promotion, Exercise, eHealth, Electronic diary